- Sweden
- /
- Healthtech
- /
- OM:QCORE
Qlucore Second Quarter 2025 Earnings: kr1.48 loss per share (vs kr0.81 loss in 2Q 2024)
Qlucore (STO:QCORE) Second Quarter 2025 Results
Key Financial Results
- Revenue: kr7.02m (down 29% from 2Q 2024).
- Net loss: kr5.95m (loss widened by 83% from 2Q 2024).
- kr1.48 loss per share (further deteriorated from kr0.81 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Qlucore's share price is broadly unchanged from a week ago.
Risk Analysis
We should say that we've discovered 4 warning signs for Qlucore (3 are significant!) that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if Qlucore might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:QCORE
Qlucore
Provides visualization-based bioinformatics data analysis tools for research and precision diagnostics in Sweden and internationally.
Adequate balance sheet slight.